Form 4: Becton Dickinson Executive Sells Shares

Michael David Garrison, EVP & Pres Med.Essntl&BioPharm at Becton Dickinson & Co, sold 1,100 shares of common stock on June 24, 2026, for $145.66 per share.

Summary

• Michael David Garrison, an executive at Becton Dickinson & Co (BDX), reported a transaction on June 24, 2026.
• The transaction involved the disposition of 1,100 shares of common stock.
• The sale price was $145.66 per share, totaling $160,226.
• Following this transaction, Mr. Garrison beneficially owns 13,172 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on February 18, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative event due to the insider sale, but the use of a Rule 10b5-1 plan mitigates significant concern.

Negatives

• An executive sold a significant number of shares, which could be perceived negatively by the market.

Risks

• The sale of shares by an executive could signal a lack of confidence in the company's future performance, although it was conducted under a pre-arranged trading plan.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a past transaction.

Management Comments

• The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 18, 2026.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a common event for executives in the healthcare and medical devices sector, particularly around periods of stock option vesting or for diversification purposes. Becton Dickinson operates in a competitive landscape, and such transactions are closely watched by investors.

Stakeholder Impact

• Shareholders: May interpret the sale as a negative signal, although the Rule 10b5-1 plan provides context that it is pre-planned.
• Employees: May view the sale by a senior executive with mixed feelings, depending on their perception of the company's prospects.
• Management: The transaction is a routine reporting requirement for executives involved in stock transactions.

Key Dates

Recommendation

The filing reports a routine stock sale by an executive under a pre-established 10b5-1 plan. While insider selling can be a negative indicator, the planned nature of this transaction and the executive retaining a substantial number of shares suggest it is unlikely to be a strong signal of negative future performance. Therefore, a 'hold' recommendation is appropriate, pending other material company news.

Keywords

Becton Dickinson, BDX, Form 4, Insider Trading, Stock Sale, Michael David Garrison, Rule 10b5-1